$PGEN News

Last published 1d ago

1d agoPGENPrecigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of ScheduleACCESS NewswirePrecigen Inc. (Nasdaq:PGEN) reported sharply improved third-quarter results late last week, driven by continuing rapid uptake of its flagship therapy PAPZIMEOS®, as the company achieved positive cash flow a quarter ahead of schedule and posted its second consecutive profitable period. The company's third-quarter PAPZIMEOS net revenue of $72.9 million was up 37% sequentially, bringing cumulative pr ...
1w agoPGENPRECIGEN, INC. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoPGENPrecigen Third Quarter 2026 Financial Results and Business Updates - PRECIGEN INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen, and welcome to the Precision Third Quarter 2026 Financial Results and Business Updates Conference Call. At this time, all lines are in listen-only mode. Following the presentation, w
2w agoPGENPrecigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4PR NewswireGERMANTOWN, Md., Oct. 28, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of
1mo agoPGENPrecigen Receives FDA Platform Technology Designation for AdenoVerse PlatformPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
2mo agoPGENPrecigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven CancersACCESS NewswireBiotech in the News: The LongviewThe Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis , is Delivering Strong Commercial Traction While Highlighting the Broader
3mo agoPGENPrecigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue GrowthPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
3mo agoPGENPrecigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4PR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
4mo agoPGENPrecigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study EncouragingACCESS NewswireMeg Flippin, Benzinga Staff WriterData reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease
5mo agoPGENPrecigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community VoicesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
5mo agoPGENPrecigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 YearsPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
5mo agoPGENPrecigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United StatesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
5mo agoPGENPrecigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare ConferencePR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
6mo agoPGENPrecigen Reports First Quarter 2026 Financial Results and Business UpdatesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
6mo agoPGENPrecigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13PR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
7mo agoPGENPrecigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 MillionACCESS NewswirePlans Underway to Expand Use to Pediatrics, Patient Redosing and European ApprovalMeg Flippin, Benzinga Staff WriterGERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. , a commercial-stage
7mo agoPGENPrecigen to Participate in a Fireside Chat with H.C. Wainwright on March 31PR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
7mo agoPGENPrecigen Reports Full Year 2025 Financial Results and Business UpdatesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
8mo agoPGENPrecigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25PR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
9mo agoPGENNew Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory PapillomatosisPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
10mo agoPGENPrecigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswirePrecigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
10mo agoPGENPrecigen to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD,...
12mo agoPGENPrecigen Reports Third Quarter 2025 Financial Results and Business UpdatesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of...
1y agoPGENPrecigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13PR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of...
1y agoPGENPrecigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory PapillomatosisPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of...
1y agoPGENPrecigen Announces Up to $125 Million Non-Dilutive FinancingPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of...
1y agoPGENPrecigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. WainwrightPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of...
1y agoPGENPrecigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory PapillomatosisPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of...
1y agoPGENFDA Approves First Immunotherapy for Recurrent Respiratory PapillomatosisFDA Press ReleasesToday, the U.S. Food and Drug Administration approved Papzimeos (zopapogene imadenovec-drba), a first-of-its-kind non-replicating adenoviral vector-based immunotherapy for the treatment of adult patients with recurrent respiratory papillomatosis (RRP).RRP is a rare, chronic disease caused by persistent human papillomavirus (HPV) 6 or 11 infection, leading to the growth of benign tumors in the resp ...
1y agoPGENPrecigen Reports First Quarter 2025 Financial Results and Business UpdatesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11thPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen Reports Full Year 2024 Financial Results and Business UpdatesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19thPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENFDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025PR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare ConferencePR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory PapillomatosisPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen Announces $79.0 Million Private Placement Offering of Convertible Preferred StockPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen Reports Third Quarter 2024 Financial Results and Business UpdatesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
1y agoPGENPrecigen to Participate in the Stifel 2024 Healthcare ConferencePR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
2y agoPGENPrecigen to Participate in the 2024 Cantor Global Healthcare ConferencePR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
2y agoPGENPrecigen, Inc. (PGEN) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoPGENPrecigen Reports Second Quarter and First Half 2024 Financial Results and Business UpdatesPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
2y agoPGENPrecigen to Announce Second Quarter and First Half 2024 Financial Results on August 14thPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
2y agoPGENPrecigen Announces Pricing of $30.0 Million Public Offering of Common StockPR NewswirePrecigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public...
2y agoPGENPrecigen Announces Proposed $30 Million Public Offering of Common StockPR NewswirePrecigen, Inc. (Nasdaq: PGEN) today announced it has commenced a $30.0 million underwritten public offering of its common stock. In addition,...
2y agoPGENPrecigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy LaunchPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
2y agoPGENPrecigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy LaunchPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
2y agoPGENPrecigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete ResponsePR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
2y agoPGENPrecigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual MeetingPR NewswirePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...